Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- BOH +3.9%, PHG +1.3%
Other news:
- TGH +42.9% (to be acquired by Stonepeak for $7.4 bln)
- HARP +20.5% (Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023)
- VERV +13.1% (announced the lifting of the clinical hold and clearance of its Investigational New Drug (IND) application)
- ARVN +5.9% (presents potential of PROTAC AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC; also upgraded to Outperform from Neutral at Wedbush)
- ORIC +5.1% (reports initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile) ROIV +5.1% (Roche acquires Telavant from Roivant for $7.1 bln)
- GH +1.4% (reports first results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer)